Last reviewed · How we verify
C-CAR-011
At a glance
| Generic name | C-CAR-011 |
|---|---|
| Also known as | CAR-CD19 |
| Sponsor | Shanghai AbelZeta Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- C-CAR011 Treatment in Subjects With ALL After HSCT (NA)
- A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects (PHASE1)
- A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects (PHASE1)
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL (PHASE1)
- Study of Safety and Efficacy of C-CAR011 in B-NHL Patients (PHASE1)
- A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |